TrialAIDS (London, England)2015

Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks.

Pablo Tebas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.